slides · global inventory
Callout
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 96,741
Current window 89,791-89,820
Pages 3,225
Rows per page 30
Component
89,791-89,820 of 96,741
21
The slide contrasts existing multi-drug combination therapies with the proposed monotherapy NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
22
The slide uses a grouped bar chart to compare hematologic response and cardiac response (NT-proBNP reduction) across four treatment categories.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
25
The slide uses a visual bridge to highlight a 67% improvement in response rates for NXC-201 compared to the average of the three competitors shown.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
33
The table highlights superior response rates (100% ORR, 70% CR) for NXC-201 compared to competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
49
The slide uses three distinct bar charts to compare IMX-110 performance against standard of care or competitor drugs in preclinical mouse models.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
06
The chart uses a dual-axis approach: left axis for interest rates (percentage), right axis for deposit balances (absolute dollars).Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations Beat · Problem1 hit
04
jetBlue | Results Presentation Deck | 17 slidesjetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · NeedLoop · Cost Of Inaction1 hit
05
The slide uses a red box to highlight the 4Q23 column and a callout box to explain the EPS impact.KeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
06
The slide uses a central circle to unify the two business segments under a shared brand value proposition.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
The slide uses a 3x3 grid layout to categorize technological capabilities.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
09
The slide uses a 2x3 grid layout with a central horizontal banner emphasizing financial performance.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
17
The slide uses a five-column layout to present key strategic pillars.Lazard | Investor Presentation Deck | 46 slides · Lazard
Conference presentation Investor relations Beat · TeamLoop · Hypothesis Test1 hit
04
The slide uses a numbered list format to present investment highlights.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank 1 hit
10
The slide uses a categorization framework to illustrate the studio's production strategy across four distinct risk/reward segments.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · Market SizeLoop · Cost Of Inaction1 hit
12
Includes a navigation bar at the top indicating this is part of a larger presentation.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Beat · ProductLoop · Cost Of Inaction1 hit
16
Slide 16 of a presentation deck.Lionsgate | SPAC Presentation Deck | 30 slides · Lionsgate
Conference presentation Investment bank Loop · Cost Of Inaction1 hit
08
The slide illustrates a sequential therapeutic approach: THIO treatment followed by CPI therapy.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
14
The slide uses a specific medical study to justify a change in clinical trial endpoint strategy.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
30
Includes details on options, warrants, and insider ownership percentages.MAIA Biotechnology | Investor Presentation Deck | 31 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
07
The slide outlines the technical workflow from sample collection to diagnostic output.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution1 hit
10
The slide uses a visual timeline/process flow to show disease progression.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
18
Slide 18 of a pitch deck.Mainz Biomed NV | Investor Presentation Deck | 24 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
08
Uses a before-after-bridge style logic to frame the solution.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
12
Focuses on clinical success in a compassionate use setting.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
13
The slide uses a timeline-based case study format to demonstrate clinical efficacy and safety.Matinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
26
Matinas BioPharma | Investor Presentation Deck | 29 slidesMatinas BioPharma | Investor Presentation Deck | 29 slides · Matinas BioPharma
Pitch deck Investor relations Beat · Impact & Next Steps1 hit
10
The slide uses two donut charts to visualize the distribution of milestone events across IND, Pre-Pivotal, and Pivotal or Later phases.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
14
The slide uses a Vitruvian-man style silhouette to represent the breadth of therapeutic applications.MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
19
The slide uses a timeline-based comparison to highlight time savings (6+ months vs 1-2 months).MaxCyte | Investor Presentation Deck | 21 slides · MaxCyte
Pitch deck Investor relations 1 hit
10
Study identifier NST002, 15 patients, open-label, intermediate formulation.NeuroSense Therapeutics | Investor Presentation Deck | 33 slides · NeuroSense Therapeutics
Pitch deck Investor relations Beat · Solution1 hit